Clinical assessment and therapy for depression

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The occurrence of depression in multiple sclerosis (MS) patients is very high, with a lifetime prevalence of up to 50%. This co-occurrence has important negative consequences for MS patients. Until now, questions about the appropriateness of classification criteria and the reliability of assessment instruments have not been completely answered. At this time, it seems worthwhile to try to clarify these points considering their relevance for clinical and therapeutic approaches to treat MS and particularly to treat depression in MS. The risk of underestimating depressive symptoms is noted and appropriate treatment is strongly recommended. More recent antidepressant drugs are preferable in treating depression in MS patients because they have a better profile of side effects. At present, combined pharmacological and psychological therapy seems to be the best approach. Recently, rTMS was also proposed for treating depression in MS patients.

Original languageEnglish
JournalNeurological Sciences
Volume27
Issue numberSUPPL. 4
DOIs
Publication statusPublished - Sep 2006

Fingerprint

Multiple Sclerosis
Depression
Therapeutics
Antidepressive Agents
Pharmacology
Psychology

Keywords

  • Assessment
  • Depression
  • Diagnosis
  • Multiple sclerosis
  • Therapy

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Cite this

Clinical assessment and therapy for depression. / Nocentini, U.

In: Neurological Sciences, Vol. 27, No. SUPPL. 4, 09.2006.

Research output: Contribution to journalArticle

@article{bc16f5ea8f7b4a3eb85e3265ece27587,
title = "Clinical assessment and therapy for depression",
abstract = "The occurrence of depression in multiple sclerosis (MS) patients is very high, with a lifetime prevalence of up to 50{\%}. This co-occurrence has important negative consequences for MS patients. Until now, questions about the appropriateness of classification criteria and the reliability of assessment instruments have not been completely answered. At this time, it seems worthwhile to try to clarify these points considering their relevance for clinical and therapeutic approaches to treat MS and particularly to treat depression in MS. The risk of underestimating depressive symptoms is noted and appropriate treatment is strongly recommended. More recent antidepressant drugs are preferable in treating depression in MS patients because they have a better profile of side effects. At present, combined pharmacological and psychological therapy seems to be the best approach. Recently, rTMS was also proposed for treating depression in MS patients.",
keywords = "Assessment, Depression, Diagnosis, Multiple sclerosis, Therapy",
author = "U. Nocentini",
year = "2006",
month = "9",
doi = "10.1007/s10072-006-0656-1",
language = "English",
volume = "27",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Clinical assessment and therapy for depression

AU - Nocentini, U.

PY - 2006/9

Y1 - 2006/9

N2 - The occurrence of depression in multiple sclerosis (MS) patients is very high, with a lifetime prevalence of up to 50%. This co-occurrence has important negative consequences for MS patients. Until now, questions about the appropriateness of classification criteria and the reliability of assessment instruments have not been completely answered. At this time, it seems worthwhile to try to clarify these points considering their relevance for clinical and therapeutic approaches to treat MS and particularly to treat depression in MS. The risk of underestimating depressive symptoms is noted and appropriate treatment is strongly recommended. More recent antidepressant drugs are preferable in treating depression in MS patients because they have a better profile of side effects. At present, combined pharmacological and psychological therapy seems to be the best approach. Recently, rTMS was also proposed for treating depression in MS patients.

AB - The occurrence of depression in multiple sclerosis (MS) patients is very high, with a lifetime prevalence of up to 50%. This co-occurrence has important negative consequences for MS patients. Until now, questions about the appropriateness of classification criteria and the reliability of assessment instruments have not been completely answered. At this time, it seems worthwhile to try to clarify these points considering their relevance for clinical and therapeutic approaches to treat MS and particularly to treat depression in MS. The risk of underestimating depressive symptoms is noted and appropriate treatment is strongly recommended. More recent antidepressant drugs are preferable in treating depression in MS patients because they have a better profile of side effects. At present, combined pharmacological and psychological therapy seems to be the best approach. Recently, rTMS was also proposed for treating depression in MS patients.

KW - Assessment

KW - Depression

KW - Diagnosis

KW - Multiple sclerosis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=33750874275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750874275&partnerID=8YFLogxK

U2 - 10.1007/s10072-006-0656-1

DO - 10.1007/s10072-006-0656-1

M3 - Article

VL - 27

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - SUPPL. 4

ER -